Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “hold” rating reiterated by analysts at Jefferies Group LLC in a note issued to investors on Thursday. They presently have a $83.00 price target on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target would indicate a potential upside of 10.73% from the company’s current price.

Several other brokerages also recently weighed in on GILD. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday. Robert W. Baird reaffirmed an “outperform” rating and issued a $87.00 target price on shares of Gilead Sciences in a report on Tuesday. Leerink Swann reaffirmed a “hold” rating and issued a $74.00 target price on shares of Gilead Sciences in a report on Tuesday. Redburn Partners assumed coverage on shares of Gilead Sciences in a report on Wednesday. They issued a “buy” rating for the company. Finally, J P Morgan Chase & Co set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Thursday. Fifteen analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $80.00.

Shares of Gilead Sciences (GILD) traded up 1.04% during trading on Thursday, reaching $74.96. The company’s stock had a trading volume of 13,870,179 shares. The firm’s 50-day moving average price is $69.34 and its 200-day moving average price is $68.59. Gilead Sciences has a one year low of $63.76 and a one year high of $82.10. The company has a market capitalization of $97.95 billion, a price-to-earnings ratio of 7.92 and a beta of 1.21. Gilead Sciences also saw unusually large options trading activity on Wednesday. Stock investors acquired 23,892 put options on the stock. This is an increase of approximately 241% compared to the average daily volume of 7,005 put options.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. Gilead Sciences’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.08 EPS. On average, equities analysts anticipate that Gilead Sciences will post $8.42 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Receives “Hold” Rating from Jefferies Group LLC” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/27/gilead-sciences-inc-gild-receives-hold-rating-from-jefferies-group-llc.html.

In other news, EVP Gregg H. Alton sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the transaction, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at $10,174,112. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director John Francis Cogan sold 9,943 shares of the firm’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total transaction of $668,666.75. Following the transaction, the director now directly owns 47,562 shares in the company, valued at $3,198,544.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 128,276 shares of company stock worth $9,190,610. Corporate insiders own 1.30% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. Rockland Trust Co. increased its position in Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock worth $12,106,000 after buying an additional 25,551 shares in the last quarter. Linscomb & Williams Inc. increased its position in Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 154 shares in the last quarter. Berkshire Asset Management LLC PA acquired a new position in Gilead Sciences during the first quarter worth about $270,000. Sigma Planning Corp increased its position in Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock worth $2,728,000 after buying an additional 2,889 shares in the last quarter. Finally, Hollencrest Securities LLC increased its position in Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 4,210 shares in the last quarter. Hedge funds and other institutional investors own 74.05% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.